The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.

  title={The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.},
  author={Sanguine Byun and Seung Ho Shin and Eunjung Lee and Jihoon W. Lee and Sung-Young Lee and Lee Farrand and Sung Keun Jung and Yong-Yeon Cho and Soo Jong Um and Hong Sig Sin and Youn-Ja Kwon and Chengjuan Zhang and Benjamin K Tsang and Ann M. Bode and Hyong Joo Lee and Ki Won Lee and Zigang Dong},
  volume={36 12},
Combination chemotherapy for the treatment of pancreatic cancer commonly employs gemcitabine with an EGFR inhibitor such as erlotinib. Here, we show that the retinoic acid derivative, ABPN, exhibits more potent anticancer effects than erlotinib, while exhibiting less toxicity toward noncancerous human control cells. Low micromolar concentrations of ABPN induced apoptosis in BxPC3 and HPAC pancreatic cancer cell lines, concomitant with a reduction in phosphorylated EGFR as well as decreased… 
CACYBP Enhances Cytoplasmic Retention of P27Kip1 to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation
Novel insights are provided into the functional role and regulatory mechanism of CacyBP in HCC and RNF41 is identified as a specific binding partner of CACYBP at exogenous and endogenous levels.
Nrdp1 Increases Ischemia Induced Primary Rat Cerebral Cortical Neurons and Pheochromocytoma Cells Apoptosis Via Downregulation of HIF-1α Protein
The data support an important role of Nrdp1 upregulation in ischemic neuronal death, and suppressing the interaction between USP8 and HIF-1α and consequently the hypoxic adaptive response of neurons may account for this detrimental effect.
Clec16a, Nrdp1, and USP8 Form a Ubiquitin-Dependent Tripartite Complex That Regulates β-Cell Mitophagy
It is reported that ubiquitination is essential for the assembly of a mitophagy regulatory complex, comprised of the E3 ligase Nrdp1, the deubiquitinase enzyme USP8, and Clec16a, a mediator of β-cell mitophile with unclear function, which relies on ubiquitin signals to promoteMitophagy and maintain mitochondrial quality control necessary for optimal β- cell function.


Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells
Results suggest that ABPN may be a promising retinoid derivative offering not only enhanced cytotoxicity, but also increased inhibition of tumor invasiveness.
Erlotinib in cancer treatment.
Clinical results available with erlotinib in the treatment of NSCLC, pancreatic, head and neck and other tumor types are reviewed, including anatomoclinical, pathologic and molecular features.
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer
In vitro, in vitro that gemcitabine induced phosphorylation of EGFR at Y845 and Y1173 that was blocked by erlotinib was found, and a novel difference pEGFR(Y845) and pEG FR(Y1173) in response to EGFR inhibition is shown.
RETRACTED ARTICLE: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27
It is found that the level of neuregulin receptor degradation protein-1 (Nrdp1) E3 ubiquitin ligase was significantly decreased in CRC tissues, compared with the adjacent normal tissues from human patients, suggesting that Nrd p1-mediated ErbB3 degradation suppresses cellular growth of CRC and that NRDp1 loss in CRC may promote tumor progression.
Gefitinib Inhibits the Proliferation of Pancreatic Cancer Cells via Cell Cycle Arrest
A mechanistic connection among events of gefitinib induced a delay in cell cycle progression and a G0/G1 arrest together with a G2/M block is suggested to provide new insights into the mechanism underlying the antiproliferative effect of g EFITinib on pancreatic cancer.
Targeting EGFR in pancreatic cancer treatment.
The epidermal growth factor receptor signaling network in pancreatic cancer is reviewed, the strategies to increase the effectiveness of epiderm growth factor receptors inhibitors, and the clinical trials of these inhibitors in pancreatIC cancer are reviewed.
USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer
Results show for the first time that the inhibition of USP8 activity or reduction inUSP8 expression can selectively kill NSCLC cells.
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
The studies suggest that HER-3 could be used as a biomarker to select patients who are most likely to respond to erlotinib therapy, as well as understanding the signaling pathways that mediate erlot inib sensitivity for pancreatic and colorectal cancers.
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
It is shown that overexpression of Nrdp1 in human breast cancer cells results in the suppression of ErbB3 levels, accompanied by the inhibition of cell growth and motility and the attenuation of signal transduction pathways.
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
A stable isogenic model of ErbB3 expression is developed in an attempt to decipher Erb B3's true contribution to pancreatic cancer tumorigenesis and to examine how this receptor affects cellular sensitivity to EGFR-targeted therapy.